Does CAPMATINIB Cause Lung neoplasm malignant? 40 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 40 reports of Lung neoplasm malignant have been filed in association with CAPMATINIB (TABRECTA). This represents 1.7% of all adverse event reports for CAPMATINIB.
40
Reports of Lung neoplasm malignant with CAPMATINIB
1.7%
of all CAPMATINIB reports
19
Deaths
7
Hospitalizations
How Dangerous Is Lung neoplasm malignant From CAPMATINIB?
Of the 40 reports, 19 (47.5%) resulted in death, 7 (17.5%) required hospitalization, and 1 (2.5%) were considered life-threatening.
Is Lung neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CAPMATINIB. However, 40 reports have been filed with the FAERS database.
What Other Side Effects Does CAPMATINIB Cause?
Death (411)
Peripheral swelling (283)
Fatigue (257)
Oedema peripheral (247)
Nausea (240)
Malignant neoplasm progression (178)
Dyspnoea (141)
Oedema (130)
Asthenia (113)
Non-small cell lung cancer (96)
What Other Drugs Cause Lung neoplasm malignant?
RANITIDINE (15,214)
ADALIMUMAB (698)
TIOTROPIUM (637)
ETANERCEPT (612)
METHOTREXATE (522)
CLOZAPINE (440)
APIXABAN (411)
ALBUTEROL (403)
INFLIXIMAB (379)
BUDESONIDE\FORMOTEROL (353)
Which CAPMATINIB Alternatives Have Lower Lung neoplasm malignant Risk?
CAPMATINIB vs CAPREOMYCIN
CAPMATINIB vs CAPSAICIN
CAPMATINIB vs CAPTOPRIL
CAPMATINIB vs CARBAMAZEPINE
CAPMATINIB vs CARBETOCIN